Newer Antiseizure Medications During Pregnancy May Pose Less Risk Than Older Drugs
Recent research indicates that certain newer antiseizure medications may pose fewer risks of birth defects during pregnancy compared to older drugs, guiding safer treatment choices for expectant mothers.
A recent study published in the journal Neurology has provided new insights into the safety of antiseizure medications used during pregnancy. The research examined both older (first-generation) and newer (second-generation) anticonvulsant drugs to determine their associated risks of birth defects when taken during the first trimester.
The study involved 7,311 women who took antiseizure medications during early pregnancy, compared to 1,311 women who did not take such drugs. Participants were interviewed multiple times—at the beginning of pregnancy, at about seven months, and within three months after delivery. Medical records confirmed the presence of birth defects, which included cleft lips, congenital heart holes, neural tube defects such as spina bifida, limb deficiencies, and other structural abnormalities.
Results showed that certain medications carry higher risks of birth defects. Valproate had the highest association, with about 9% of infants exposed developing major malformations. Phenobarbital was linked to a 6% risk. Among newer drugs, topiramate was associated with a 5% incidence of birth defects, whereas lamotrigine was linked to a 2% rate. When compared directly to lamotrigine, valproate increased the risk of birth defects over fivefold, phenobarbital nearly tripled the risk, and topiramate more than doubled it.
These findings suggest that some newer antiseizure medications, such as levetiracetam, oxcarbazepine, gabapentin, and zonisamide, may be safer options during pregnancy, as they did not show an increased risk of major birth defects. However, for drugs like lacosamide and pregabalin, the data was insufficient to draw definitive conclusions, calling for further research.
The researchers acknowledged a limitation in their study: participants were enrolled months after conception, meaning early pregnancy losses and associated malformations might have been underreported. Nonetheless, the study emphasizes the importance of carefully selecting antiseizure medications for women who are pregnant or planning pregnancy, to reduce the risk of birth defects while effectively managing seizures.
According to Sonia Hernandez-Diaz, MD, DrPH from Harvard T.H. Chan School of Public Health, "Seizure control is critical during pregnancy, but safety of medications is equally important. Our study helps inform healthcare providers and women about the potential risks associated with different anticonvulsants to support safer choices."
For more details, the full study can be accessed through Neurology: doi: 10.1212/WNL.0000000000213786.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Brain Pathway Links Pain to Emotional Suffering
Scientists have identified a brain circuit that links physical pain to emotional suffering, offering new insights into chronic pain and potential treatments for affective pain disorders.
Rising Uninsured Rates to Challenge Local Healthcare Systems
An anticipated rise in uninsured Americans is expected to strain healthcare systems nationwide, particularly impacting rural communities and vulnerable populations. Learn about the challenges and policy implications.
New Imaging Techniques Uncover How Tiny Brain Vessels Pulse to Control Blood Flow
A new study utilizes laser speckle contrast imaging to uncover the rhythmic pulsations of tiny brain vessels, offering insights into blood flow regulation and brain health.
Wegmans Issues Recall for Cheese Products Due to Listeria Contamination Risk
Wegmans has issued a recall for several cheese products due to potential Listeria contamination. Consumers are advised not to eat the affected items and return them for a refund. Learn more about the recall and Listeria risks.